hepatitis C

Gilead Sciences Falls Amid Worries Over Hep-C Drug Price
TheStreet.com
Tue, 10/14/14 - 11:22 am
Gilead Sciences
hepatitis C
drug pricing
Harvoni
If AbbVie Discounts its Hep C Drug, Would Pricing Reach a Tipping Point?
WSJ Pharmalot
Tue, 10/14/14 - 09:51 am
AbbVie
drug pricing
hepatitis C
Gilead Sciences
BIT225 Trial Results Show Effective Cure of Hepatitis C
Drug Discovery and Development
Mon, 10/13/14 - 07:32 am
Biotron
BIT225
hepatitis C
Gilead’s new drug is even pricier than Sovaldi
MarketWatch
Sat, 10/11/14 - 08:18 am
Gilead
Harvoni
hepatitis C
Gilead Wins U.S. Approval for Hepatitis C Combo Pill
Bloomberg
Fri, 10/10/14 - 05:51 pm
Gilead Sciences
FDA
Harvoni
hepatitis C
As Hepatitis Pill Harvoni Joins Sovaldi, States Erect Medicaid Hurdles
Forbes
Fri, 10/10/14 - 09:10 am
Harvoni
Sovaldi
Medicaid
hepatitis C
Gilead Sciences
Merck to release hep C data
Yahoo/Investors Business Daily
Wed, 10/8/14 - 08:32 pm
Merck
hepatitis C
Salix’s Xifaxan Sales Expected To Go Downhill
Bidness Etc.
Wed, 10/8/14 - 11:04 am
Salix
Xifaxan
hepatitis C
Gilead Sciences: Here Comes the Competition
Barron's
Tue, 10/7/14 - 01:21 pm
Gilead Sciences
hepatitis C
Sovaldi
Merck
AbbVie
Idenix
Bristol-Myers Squibb
Achillion
Bristol-Myers Squibb pulls FDA filing for asunaprevir, citing rapidly evolving hepatitis C field
First Word Pharma
Tue, 10/7/14 - 08:48 am
Bristol-Myers Squibb
asunaprevir
hepatitis C
Sovaldi may be cost-effective, but the U.K. can't afford it, documents say
Fierce Pharma
Tue, 10/7/14 - 08:09 am
Sovaldi
UK
drug pricing
Gilead Sciences
hepatitis C
Novartis drops out of hep C race, punting a $440M Enanta pact
Fierce Biotech
Wed, 10/1/14 - 09:19 am
Novartis
hepatitis C
Enanta Pharmaceuticals
EDP-239
alisporivir
Gilead’s Hepatitis C Combination Wins EU Agency Backing
Bloomberg
Fri, 09/26/14 - 09:02 am
Gilead Sciences
hepatitis C
Europe
Sovaldi
ledipasvir
Generic Sovaldi makers could pocket upwards of $600m says analyst
In-Pharma Technologist
Thu, 09/25/14 - 09:25 am
generics
Sovaldi
Gilead Sciences
hepatitis C
Mylan
Strides Arcolab
Cadila
Cipla
Hetero Labs
Ranbaxy
Sequent Scientific
Why Gilead Sciences Could Gain 30%
Barron's
Fri, 09/19/14 - 02:18 pm
Gilead Sciences
SOF/LDV
hepatitis C
Dropout rate on $1,000-a-day pill jumps during transition to ‘real world’
Marketwatch
Wed, 09/17/14 - 04:32 pm
Gilead Sciences
Sovaldi
drug pricing
hepatitis C
Gilead Deal to Sell Sovaldi in Poor Countries Meets Criticism
WSJ Pharmalot
Mon, 09/15/14 - 07:21 pm
Gilead Sciences
drug pricing
hepatitis C
Sovaldi
U.S. Hepatitis Problem to Continue Driving These 4 Top Stocks
24/7 Wall St
Mon, 09/15/14 - 11:36 am
hepatitis C
Gilead Sciences
AbbVie
Achillion
Merck
Sovaldi
Idenix
Gilead signs pact with 7 firms for cheap copies of hepatitis C drug
Yahoo/Reuters
Mon, 09/15/14 - 08:49 am
Gilead Sciences
Sovaldi
generics
hepatitis C
Cipla
Ranbaxy
Cadila
Mylan Labs
Strides Arcolab
Hetero Drugs
Sequent Scientific
Gilead to raise price for new hepatitis C drug above $84,000
Yahoo/Reuters
Fri, 09/12/14 - 07:10 pm
Gilead
Sovaldi
drug pricing
hepatitis C

Pages